Prognostic value of dynamic susceptibility contrast-enhanced and diffusion-weighted mr imaging in patients with glioblastomas

American Journal of Neuroradiology

Volumn 36, Issue 7, 2015, Pages 1247-1252

  Coban X G ^a,b   Mohan, S ^b   Kural, F ^a,b   Wang, S ^b   O'Rourke, D M ^c   Poptani, H ^b  

^a BASKENT UNIVERSITY   (Turkey)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BRAIN BLOOD VOLUME; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; ECHO PLANAR IMAGING; FEMALE; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; INTERMETHOD COMPARISON; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SCANNER; OVERALL SURVIVAL; PERFUSION WEIGHTED IMAGING; PROGNOSIS; PROGNOSTIC ASSESSMENT; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TIME TO TREATMENT; TREATMENT PLANNING; BLOOD VOLUME; BRAIN TUMOR; MORTALITY; PATHOLOGY; PROCEDURES; VASCULARIZATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BLOOD VOLUME; BLOOD VOLUME DETERMINATION; BRAIN NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; YOUNG ADULT;

EID: 84937424276     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A4284     Document Type: Article

References (48)

1. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005;109:93-108
2. Behin A, Hoang-Xuan K, Carpentier AF, et al. Primary brain tumours in adults. Lancet 2003;361:323-31
3. Stark AM, Nabavi A, Mehdorn HM, et al. Glioblastoma multiforme: report of 267 cases treated at a single institution. Surg Neurol 2005;63:162-69
4. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1999;1:44-51
5. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection of resection and survival. J Neurosurg 2001;95:190-98
6. Mangiola A, Maira G, De Bonis P, et al. Glioblastoma multiforme in the elderly: a therapeutic challenge. J Neurooncol 2006;76:159-63
7. Galanis E, Buckner J, Kimmel D, et al. Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Int J Oncol 1998;13:717-24
8. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63:6962-70
9. Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247:490-98
10. Spampinato MV, Schiarelli C, Cianfoni A, et al. Correlation between cerebral blood volume measurements by perfusion-weighted magnetic resonance imaging and two-year progression-free survival in gliomas. Neuroradiol J 2013;26:385-95
11. Bisdas S, Kirkpatrick M, Giglio P, et al. Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease? AJNR Am J Neuroradiol 2009;30:681-88
12. Bampoe J, Bernstein M. The role of surgery in low grade gliomas. J Neurooncol 1999;42:259-69
13. Murakami R, Hirai T, Sugahara T, et al. Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one versus two-parameter pilot method. Radiology 2009;251: 838-45
14. Bode MK, Ruohonen J, Nieminen MT, et al. Potential of diffusion imaging in brain tumors: a review. Acta Radiol 2006;47:585-94
15. Murakami R, Sugahara T, Nakamura H, et al. Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging. Radiology 2007;243:493-99
16. Higano S, Yun X, Kumabe T, et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006;241:839-46
17. Nakamura H, Murakami R, Hirai T, et al. Can MRI-derived factors predict the survival in glioblastoma patients treated with postoperative chemoradiation therapy? Acta Radiol 2013;54:214-20
18. Oh J, Henry RG, Pirzkall A, et al. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 2004;19:546-54
19. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96
20. Paul I, Bhattacharya S, Chatterjee A, et al. Current understanding on EGFR and Wnt/-catenin signaling in glioma and their possible crosstalk. Genes Cancer 2013;4:427-46
21. Yiin JJ,HuB, Schornack PA, et al. ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain. Mol Cancer Ther 2010;9:929-41
22. Johnson G, Wetzel SG, Cha S, et al. Measuring blood volume and vascular transfer constant from dynamic, T(2)∗-weighted contrastenhanced MRI. Magn Reson Med 2004;51:961-68
23. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2∗-weighted MR imaging. Radiology 1999;211: 791-98
24. Rosen BR, Belliveau JW, Buchbinder BR, et al. Contrast agents and cerebral hemodynamics. Magn Reson Med 1991;19:285-92
25. Rosen BR, Belliveau JW, Vevea JM, et al. Perfusion imaging with NMR contrast agents. Magn Reson Med 1990;14:249-65
26. Spampinato MV, Wooten C, Dorlon M, et al. Comparison of firstpass and second-bolus dynamic susceptibility perfusion MRI in brain tumors. Neuroradiology 2006;48:867-74
27. Wetzel SG, Cha S, Johnson G, et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002;224:797-803
28. Wang S, Kim S, Chawla S, et al. Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2011;32:507-14
29. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. AJNR Am J Neuroradiol 2004;25:214-21
30. Law M, Oh S, Babb JS, et al. Low-grade gliomas: dynamic susceptibility weighted contrast-enhanced perfusion MR imaging-prediction of patient clinical response. Radiology 2006;238:658-67
31. Law M, Yang S, Babb JS, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrastenhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004;25:746-55
32. Mangla R, Ginat DT, Kamalian S, et al. Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes. J Neurooncol 2014; 116:325-31
33. Hirai T, Murakami R, Nakamura H, et al. Prognostic value of perfusionMRimaging of high-grade astrocytomas: long-term follow-up study. AJNR Am J Neuroradiol 2008;29:1505-10
34. Cha S, Tihan T, Crawford F, et al. Differentiation of low grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2005;26:266-73
35. Essock-Burns E, Philips JJ, Molinaro AM, et al. Comparison of DSCMRIpost-processing techniques in predicting microvascular histopathology in patients newly diagnosed with GBM. J Magn Reson Imaging 2013;38:388-400
36. Morita N, Wang S, Chawla S, et al. Dynamic susceptibility contrast perfusion weighted imaging in grading of non-enhancing astrocytomas. J Magn Reson Imaging 2010;32:803-08
37. Wu WC, Chen CY, Chung HW, et al. Discrepant MR spectroscopic and perfusion imaging results in a case of malignant transformation of cerebral glioma. AJNR Am J Neuroradiol 2002;23:1775-78
38. Nelson SJ. Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI. NMR Biomed 2011;24:734-49
39. Yamasaki F, Sugiyama K, Ohtaki M, et al. Glioblastoma treated with postoperative radiochemotherapy: prognostic value of apparent diffusion coefficient at MR imaging. Eur J Radiol 2010;73:532-37
40. Pierallini A, Bonamini M, Pantano P, et al. Radiological assessment of necrosis in glioblastoma: variability and prognostic value. Neuroradiology 1998;40:150-53
41. Ru P, Williams TM, Chakravarti A, et al. Tumor metabolism of malignant gliomas. Cancers 2013;5:1469-84
42. Miyagami M, Katayama Y. Angiogenesis of glioma: evaluation of ultrastructural characteristics of microvessels and tubular bodies (Weibel-Palade) in endothelial cells and immunohistochemical findings with VEGF and p53 protein. Med Mol Morphol 2005; 38:36-42
43. Kapoor GS, Gocke TA, Chawla S, et al. Magnetic resonance perfusion weighted imaging defines angiogenic subtypes of oligodendroglioma according to1p19q and EGFR status. J Neurooncol 2009; 92:373-86
44. Abdulrauf SI, Edvardsen K, Ho KL, et al. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg 1998;88:513-20
45. Shaw EG, Tatter SB, Lesser GJ, et al. Current controversies in the radiotherapeutic management of adult low-grade glioma. Semin Oncol 2004;31:653-58
46. Stupp R, Baumert BG. Promises and controversies in the management of low-grade glioma. Ann Oncol 2003;14:1695-96
47. Xie K, Yang J, Zhang ZG, et al. Semi-automated brain tumor and edema segmentation using MRI. Eur J Radiol 2005;56:12-19
48. Kaus MR, Warfield SK, Nabavi A, et al. Automated segmentation of MR images of brain tumors. Radiology 2001;218:586-91